Work

Combination low-intensity chemotherapy plus inotuzumab ozogamicin, blinatumomab and rituximab for pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Year: 2024

Type: article

Source: Haematologica

DOI: 10.3324/haematol.2023.284950

Authors: Amber Gibson, Cesar Nunez, Lindsay Robusto, Brianna Kammerer, Miriam Garcia, Michael Roth, Rachna Sheth, Priti Tewari, Aline Hittle, Laurie Toepfer, Romeo Torres, Nicholas J. Short, Elias Jabbour, Nitin Jain, Branko Cuglievan, David McCall

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Acute Lymphoblastic Leukemia research

Subfield: Public Health, Environmental and Occupational Health

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $2,157

Funders: Amgen, Pfizer

OpenAlex ID: W4398262008

FWCI: 2.544

Cites: 19

Cited by: 7

Related to: 10